Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors

[1]  W. K. Henry,et al.  Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W. Haynes.  Triglyceride-rich lipoproteins and vascular function. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[3]  D. Playford,et al.  Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[4]  Y. Sakai,et al.  Possible Relationship between Insulin Resistance and Remnant‐Like Lipoprotein Particles in Coronary Endothelial Dysfunction , 2002, Clinical cardiology.

[5]  John M Williamson,et al.  Protease inhibitors and cardiovascular outcomes in patients with HIV-1 , 2002, The Lancet.

[6]  D. Freedman,et al.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. , 2002, The American journal of cardiology.

[7]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[8]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[9]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[10]  F. Perticone,et al.  Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients , 2001, Circulation.

[11]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[12]  A Ammassari,et al.  Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. , 2000, AIDS.

[13]  K. Kostner,et al.  Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. , 2000, The American journal of cardiology.

[14]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[15]  J. Stein,et al.  Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. , 1999, Circulation.

[16]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[17]  H. Schmidt,et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.

[18]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[19]  K. Tashima,et al.  Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). , 1999, Journal of acquired immune deficiency syndromes.

[20]  J. Hokanson,et al.  Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. , 1999, Circulation.

[21]  F. Ohsuzu,et al.  Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. , 1998, The American journal of cardiology.

[22]  D. Freedman,et al.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[23]  K. Kugiyama,et al.  Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. , 1998, Circulation.

[24]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[25]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[26]  J. Tardif,et al.  Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes , 1998 .

[27]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[28]  R. Krauss,et al.  Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[30]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[31]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[32]  D. Spiegelhalter,et al.  Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. , 1995, British heart journal.

[33]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[34]  M. Schambelan,et al.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. , 2000 .